Related Experiment Video
Updated: Oct 23, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
Developing a Generative Model Utilizing Self-attention Networks: Application to Materials/Drug Discovery.
1Ichihara Research Laboratories, JNC Petrochemical Corporation, 5-1, Goi Kaigan, 290-8551, Ichihara, Chiba, Japan.
A novel Variational Autoencoding Transformer (VAT) model accurately generates existing and novel molecules. This versatile generative model requires no heuristic settings, aiding drug discovery and materials science.
Area of Science:
- Artificial Intelligence
- Computational Chemistry
- Drug Discovery
Background:
- Generative models are crucial for molecular design.
- Existing models may require complex parameter tuning.
- Developing versatile and accurate generative models is an ongoing challenge.
Purpose of the Study:
- To introduce a new generative model, the Variational Autoencoding Transformer (VAT).
- To apply the VAT model to the task of molecular generation.
- To demonstrate the model's accuracy and versatility without heuristic settings.
Main Methods:
- Combining Variational Autoencoder (VAE) networks with Transformer architectures.
- Training the VAT model on molecular datasets.
- Implementing fine-tuning and latent space mixing strategies for directed generation.
Main Results:
- The VAT model accurately reproduces input molecules.
- The VAT model generates novel molecules with high fidelity from a prior.
- The model demonstrates optimal performance without heuristic settings, applicable to diverse datasets.
Conclusions:
- The Variational Autoencoding Transformer is a powerful and adaptable tool for molecular generation.
- The demonstrated strategies offer practical pathways for materials and drug discovery.
- The VAT model's ease of use and high accuracy make it a valuable asset for researchers.
Related Concept Videos
Drug Discovery: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drug Dependence

